Conectar con nosotros

koronabirusa

Frantziako COVID kasu berriak 100,000 izan litezke egunean: Gobernuko mediku aholkularia

Argitaratutako

on

Baliteke Frantziak egunero 100,000 COVID-19 kasu berri izatea - azken datu ofizialaren bikoitza - Jean-François Delfraissy irakasleak, gobernuari pandemia horri buruz aholkatzen duen kontseilu zientifikoa zuzentzen duena, esan zion RTL irratiari astelehenean (urriak 26), idazten du Sudip Kar-Gupta.

«Ziurrenik egunean 50,000 kasu baino gehiago daude. Batzorde zientifikoan kalkulatzen dugu egunean 100,000 kasu gehiago ditugula ", esan du Delfraissyk.

Frantzia, euroguneko bigarren ekonomia handiena, COVID-19 birusaren berpiztea geldiarazteko blokeo neurriak gehiago estutu nahi ote dituen aztertzen ari da, jada gaueko toki deialdiak ezarri baitizkie Paris barne, hiri nagusiei.

Osasun Ministerioak igandean 52,010 berretsi zituen koronabirus infekzio berri berri bat eman zuen igandean azken 24 orduetan, Europan zehar kasuen bigarren olatu bat areagotzen ari baita.

Kasu berriek 1,138,507 izatera iritsi ziren, eta Frantziak Argentina eta Espainia gainditu zituen munduko bosgarren kasurik altuena erregistratzean.

Ministerioak esan duenez, igandera arteko 116 orduetan 24 pertsona hil dira koronabirusaren infekzioagatik, 137 egun lehenago baino gutxiago, eta guztira 34,761 heriotza izan ziren.

koronabirusa

Alemaniako estatuek COVID-19 blokeoa luzatzearen alde egiten dute Gabonetako aukerak bultzatzeko

Argitaratutako

on

By

Alemaniako 16 estatu federal askok COVID-19 pandemiaren hedapena moteltzeko eta Gabonetan familia topaketak ahalbidetzeko ixte partziala luzatzearen alde agertu dira, bi estatuko lehen ministroek astelehenean (azaroak 23) esan zutenez. Koalizio kontserbadore-sozialdemokrata batek gobernatzen duen Alemaniak hilabeteko "blokeo-lite" bat ezarri zuen azaroaren 2tik aurrera. Infekzio kopuruak ordutik goiti dira baina ez dira gutxitu, idatzi Christian Goetz, Thomas Seythal eta Kirsti Knolle.

"Azaroko itxierak zerbait ekarri du, (infekzio) zenbakiak apalak dira baina altuak dira", adierazi dio Manuela Schwesig, Mecklenburg-Vorpommern iparraldeko estatuko lehen ministroak Deutschlandfunk (DLF) irratiari.

"Hori dela eta, estatu askok uste dute azaroko geldialdiak jarraitu behar duela, batez ere arrisku arloetan", esan du sozialdemokratak. Reiner Haseloff Saxonia-Anhalt estatuko lehen ministroak, Angela Merkel kantzilerraren kontserbadoreetako kideak, prentsaurrekoan esan zuen akordio orokorra zegoela gaur egungo murrizketak hiru aste inguru luzatu beharko liratekeela. Estatuko lehen ministroek eta Merkelek asteazkenean aztertuko dituzte neurriak.

Abenduaren 20ra arte luzatu ditzakete, Reutersek lortutako kristau-demokratek eta sozialdemokratek egindako proposamenen arabera. Tabernak eta jatetxeak itxita daude azaroko itxialdiaren azpian, baina eskolak eta dendak zabalik daude. Topaketa pribatuak gehienez bi etxetako 10 lagunera mugatuta daude. Azken 10,864 orduetan berretsitako koronabirusen kasuak 929,133 eta 24 igo dira, aurreko astean aurreko igandean izandako igoera baino 40 gehiago, gaixotasun infekziosoen Robert Koch Institutuko (RKI) datuek astelehenean (azaroak 23) erakutsi zuten.

Hildakoen kopurua 90 eta 14,112ra igo zen Alemanian, 83 milioiko herrialdea Europako ekonomiarik handiena duena. Enpresei laguntza ekonomikoa abendura arte luzatu ahal izango zaiela esan du Peter Altmaier Ekonomia ministroak DLFn. COVID-19 txertoak prestatzeko abendu erdialderako amaitu beharko lirateke inokulazioak berehala hasi ahal izateko txertoak urtea amaitu baino lehen eskuragarri egongo balira, Jens Spahn Osasun ministroak kazetariei esan dienez. Pfizerrek eta BioNTech-ek AEBetako COVID-19 txertoa larrialdian erabiltzeko baimena emateko eskaerak bultzatu ditu itxaropenak.

Jarraitu irakurtzen

koronabirusa

AstraZenecak dio COVID-19 'munduko txertoa'% 90ean eraginkorra izan daitekeela

Argitaratutako

on

By

AstraZeneca said on Monday (23 NOvember) its COVID-19 vaccine could be around 90% effective, giving the world’s fight against the global pandemic a new weapon, cheaper to make, easier to distribute and faster to scale-up than rivals, write Kate Holton, Josephine Mason and Kate Kelland.

The British drugmaker said it will have as many as 200 million doses by the end of 2020, around four times as many as U.S. competitor Pfizer. Seven hundred million doses could be ready globally as soon as the end of the first quarter of 2021. “This means we have a vaccine for the world,” said Andrew Pollard, director of the Oxford University vaccine group that developed the drug. The vaccine was 90% effective in preventing COVID-19 when it was administered as a half dose followed by a full dose at least a month later, according to data from late-stage trials in Britain and Brazil. No serious safety events were confirmed, the company said.

The vaccine’s cost to governments works out at just a few dollars a shot, a fraction of the price of shots from Pfizer and Moderna, which use a more unconventional technology. It can also be transported and stored at normal fridge temperatures, which proponents say would make it easier to distribute, especially in poor countries, than Pfizer’s, which needs to be shipped and stored at -70C. The faster roll-out means both rich and poor countries that had been drawing up plans to ration vaccines can distribute them more widely, helping to eventually halt the massive social and economic disruption of a pandemic that has killed 1.4 million people.

“The bulk of the vaccine rollout programme will be in January, February, March. And we hope that sometime after Easter things will be able to start to get back to normal,” said Matt Hancock, health secretary of Britain which has pre-ordered 100 million doses for its 67 million people.

Some signs AstraZeneca vaccine durability could be a year - chief investigator Oxford COVID-19 vaccine efficacy would look higher if trial tested for severe virus See more stories In poor countries, where the logistics of distributing rival vaccines posed a bigger challenge, the effect of a cheaper and easier alternative could be even more pronounced. Zahid Maleque, health minister of Bangladesh, which is buying in 30 million doses of the AstraZeneca vaccine made in India, called the findings “really good news”.

“The big advantage of having the vaccine is that it can be stored, transported and handled at 2-8 degrees Celsius, and we have that storage facility,” he said. “

The results showed the effectiveness of AstraZeneca’s vaccine depended on the dosing, and fell to just 62% when given as two full doses rather than a half-dose first. Scientists cautioned, however, against seeing this as evidence that it would be less useful than rivals. Vaccines from Pfizer and Moderna each prevented about 95% of cases according to interim data from their late-stage trials. The researchers did not say what proportion of the 131 cases of COVID-19 in the study received the smaller initial dose. “I think it is a real fool’s errand to start trying to pick these three (Pfizer/Moderna/Astra) apart on the basis of snippets of phase 3 data from press releases,” said Danny Altmann, professor of immunology at Imperial College London. “For the bigger picture, my suspicion is that by the time we are a year down the line, we’ll be using all three vaccines with about 90% protection - and we’ll be a lot happier.”

Researchers don’t know the exact reason why a smaller first dose proved more effective. “There are some examples where changing the way you prime the immune system, can result in a better response,” Pollard said. Pascal Soriot, Astra’s chief executive, said it was good news, as more people could be vaccinated faster with a limited supply. Shares and oil prices rose amid hopes another vaccine candidate would revive the global economy with U.S. stock futures trading higher and the STOXX index of Europe’s 600 largest shares gaining 0.5% to its highest since February. AstraZeneca’s own shares fell 1.8% as traders perceived the efficacy data as disappointing compared with rivals.

Pfizer and Moderna set the bar for success sky-high. The US Food and Drug Administration has said any shot would need to prevent disease or decrease severity in at least 50% of those vaccinated. The AstraZeneca vaccine uses a modified version of a chimpanzee common cold virus to deliver instructions to cells to fight the target virus, a traditional approach to vaccine development and different from the path taken by Pfizer and Moderna, which rely on new technology known as messenger RNA (mRNA). AstraZeneca, one of Britain’s most valuable listed companies, will now immediately prepare regulatory submission of the data to authorities around the world that have a framework in place for conditional or early approval.

It will also seek an emergency use listing from the World Health Organization to speed up availability in low-income countries. In parallel, the full analysis of the interim results is being submitted for publication in a peer-reviewed journal. The US Food and Drug Administration is likely to approve in mid-December the distribution of the vaccine made by Pfizer, according to a top official of the US government’s vaccine development effort.

Jarraitu irakurtzen

catalan

Batzordeak 2.55 mila milioi euroko berme espainiarra onartu du zenbait autonomori eta enpresei konpentsatzeko, koronabirusaren agerraldia dela eta jasandako kalteengatik.

Argitaratutako

on

Europako Batzordeak onartu du, EBko estatu-laguntzei buruzko arauen arabera, 2.55 mila milioi euroko Espainiako egitasmoa, konposizio judizialeko akordioak jarraitzen ari diren zenbait autonomo eta enpresa konpentsatzeko, koronabirusaren agerraldia dela eta jasandako kalteengatik. Konpentsazioak gainbegiratutako finantza-erakundeek emandako mailegu berrien itzulketarako berme publikoak eta Errenta Finkoko Merkatu Alternatiboari buruzko ohar berriak izango ditu. Eskemaren arabera, konkurtso prozedura judizialaren ondoren hartzekodunekin hartzekodunekin onartutako 15,000 autonomo eta enpresari inguru konpentsatuko dira 14ko martxoaren 20tik ekainaren 2020ra bitartean sortutako kalteengatik.

Epe hori Espainiako Gobernuak birusaren hedapena mugatzeko neurri murriztaileak ezarri zituenekoarekin bat dator. Batzordeak neurria ebaluatu zuen 107. artikuluko 2. paragrafoko b) artikulua Europar Batasuneko Funtzionamenduari buruzko Tratatuaren bidez, Batzordeak estatu kideek enpresa zehatzak edo sektore zehatzak konpentsatzeko emandako salbuespeneko gertakariek, hala nola koronabirusaren agerraldiak, eragindako kalteengatik konpentsatzeko emandako estatu laguntzak onartzeko aukera ematen du. Batzordeak ikusi du Espainiako eskemak koronabirusaren agerraldiaren murrizketekin lotura zuzena duten kalteak konpentsatuko dituela.

Neurria proportzionala dela ere ikusi du, aurreikusitako kalte-ordainak ez dituelako kalteak konpontzeko beharrezkoa dena gainditzen. Horregatik, Batzordeak ondorioztatu zuen eskema bat datorrela EBko estatu laguntzen arauekin. Informazio gehiago eskuragarri egongo da Batzordean lehiaketa webgunean, in the Kasu publiko erregistro, SA.59045 kasuaren azpian.

Jarraitu irakurtzen
iragarki

Facebook

Twitter

Modako